With post-pandemic Medicaid enrollments on the decline and expected to fall further, revenue cycle leaders warn that ...
When hospitals overcharge insurers for drugs they bought at deep 340B discounts, taxpayers, employers, and insured patients ...
Eli Lilly said last night it will deny 340B Drug Pricing Program discounts to providers that do not meet its documentation ...
The 340B Drug Pricing Program is under pressure from multiple directions: pharmacy benefit manager litigation, drugmaker contract pharmacy restrictions, and a federal rebate pilot that courts have ...
Drug manufacturers participating in the Section 340B Drug Pricing Program now face a significant new litigation risk under the False Claims Act (“FCA”). In a recent decision, Adventist Health System v ...
The 340B Drug Discount Program was designed to help safety-net providers make drugs available to low-income patients and earn revenue. Drug manufacturers have put restrictions on which pharmacies ...
Effective compliance now spans transaction eligibility, OPAIS synchronization, Medicaid exclusion validation, cost-report ...
On December 29, 2025—just three days before the 340B Rebate Model Pilot Program (the Rebate Program) was set to begin—the U.S. District Court for the District of Maine issued an order granting a ...
Minnesota's 340B drug discount program faces scrutiny as small clinics struggle and large hospitals profit, sparking ...
A federal judge in Missouri has denied a request by AstraZeneca Pharmaceuticals LP to compel several nonparty hospitals and ...
Jacksonville Journal-Courier on MSN
Federal drug discount expansion proposal may cost Illinois millions, agency head says
Pending legislation to expand providers’ access to discounted drugs has sparked strong lobbying campaigns for and against the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results